Mark is a co-founder of Sionna and serves as Vice President of Medicinal Chemistry. He has nearly 30 years of experience creating biopharmaceutical drugs. Formerly, he was the U.S. head of medicinal chemistry at Sanofi where he oversaw a diverse group of scientists that advanced forward multiple development candidates in oncology and rare disease. He also contributed to several external partnerships including Principia, MyoKardia, Lead Pharma, and DiCE.
Mark was a founding member of Array Biopharma (acquired by Pfizer) where he led several programs into clinical development (ARRY-797, ARRY-382 and pexmetinib). He began his career at Amgen where he created and led the highspeed synthesis group. Mark received his Ph.D. in chemistry from the University of Minnesota and his B.S. from Macalester College.